[The dilemma of first-line chemotherapy in advanced non-small-cell lung cancer: are third-generation drugs all the same?]

Tumori. 2008 May-Jun;94(3):5-14.

[Article in Italian]

Authors

Francesco Grossi¹, Filippo de Marinis, Luciano Frontini, Cesare Gridelli

Affiliation

¹ Oncologia Medica A, Disease Management Team, Lung Cancer, Istituto Nazionale per la Ricerca sul Cancro, Genova.

PMID: 18705422

No abstract available

Publication types

Review

MeSH terms

Antimetabolites, Antineoplastic / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents, Phytogenic / administration & dosage
Carboplatin / administration & dosage
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cisplatin / administration & dosage
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Docetaxel
Drug Administration Schedule
Gemcitabine
Humans
Lung Neoplasms / drug therapy*
Paclitaxel / administration & dosage
Taxoids / administration & dosage
Vinblastine / administration & dosage
Vinblastine / analogs & derivatives
Vinorelbine

Substances

Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Taxoids
Deoxycytidine
Docetaxel
Vinblastine
Carboplatin
Paclitaxel
Cisplatin
Vinorelbine
Gemcitabine